Noble Capital Markets Initiates Coverage On YS Biopharma Co With Outperform Rating, Announces Price Target of $5.25
BenzingaNov 13, 2023 12:06 ET
YS Biopharma Co Analyst Ratings
BenzingaNov 13, 2023 12:03 ET
No Data